Tonix Pharmaceuticals Holding (TNXP)
Nasdaq Market Closed
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company that develops and commercializes medicines across central nervous system disorders, immunology, infectious disease, and rare disease indications. The company combines marketed products with a development pipeline, giving it exposure to both current specialty pharmaceutical sales and higher-risk clinical research programs.
A central asset in Tonix’s portfolio is TONMYA, a sublingual cyclobenzaprine product approved for fibromyalgia. The company is also evaluating the therapy in additional stress-related and mood-related conditions, including major depressive disorder and acute stress disorder. In the migraine market, Tonix markets Zembrace SymTouch and Tosymra, acute migraine treatments that provide commercial infrastructure and product experience in neurology.
Beyond central nervous system disorders, Tonix is advancing immunology and infectious disease candidates. Its pipeline includes TNX-4800, a monoclonal antibody program being developed for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor being studied for the prevention of kidney transplant rejection. These programs reflect the company’s broader strategy of pursuing immune-mediated and infection-related conditions where new preventive or therapeutic options may be needed.
Tonix is best understood as a small-cap biotechnology company with a mix of approved, marketed, clinical-stage, and discovery-stage assets. Its valuation is influenced by prescription growth, clinical trial results, regulatory milestones, financing needs, and the competitive landscape in fibromyalgia, migraine, transplant medicine, and infectious disease prevention. The company’s distinctive feature is the breadth of its pipeline across CNS and immunology rather than reliance on a single therapeutic area.
Last updated
- Market Cap
- 182.68M
- P/E
- —
- P/FCF
- —
- P/S
- 10.41
- Enterprise Value
- -2.79M
- Sector
- Materials
- Industry
- Pharmaceutical Preparations
- Address
- 200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NJ, 07922
Bay Area Lyme Foundation Raises $900,000 at LymeAid 2026, Presenting Inaugural Neil L. Spector, MD, Legacy Award and $300,000 in Emerging Leader Grants
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence
Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia
Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction
2 Stocks Riding the Biotech Surge With Major Catalysts Ahead
Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th
Global Artificial Intelligence in Drug Commercialization Market to Observe Stupendous Growth at a CAGR of ~24% by 2032 | DelveInsight
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 182.68M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- -2.79M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.8
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 10.41
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 0.02
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- -0.16
- EPS
- -9.25
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -130.64M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -64.89%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -57.15%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 6.99
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 6.86
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 6.26
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 456.56K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 11.46
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 6.88M | 5.39M | 3.29M | 2M | 2.43M |
| Gross profit | 5.3M | 4.33M | 1.92M | -1.27M | 1.49M |
| Operating income | -41.54M | -48.29M | -33.07M | -28.3M | -16.05M |
| EBITDA | -40.98M | -47.8M | -32.61M | -27.81M | -15.56M |
| Net income | -40.19M | -46.91M | -32.01M | -28.27M | -16.83M |
| Basic EPS | -2.93 | -4.15 | -3.59 | -3.86 | -2.84 |
| Diluted EPS | -2.93 | -4.15 | -3.59 | -3.86 | -2.84 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 257.91M | 277.17M | 252.44M | 187.36M | 192.87M |
| Total liabilities | 30.78M | 32.02M | 21.3M | 19.36M | 12.47M |
| Total equity | 227.14M | 245.15M | 231.14M | 168M | 180.4M |
| Cash & equivalents | 185.47M | 207.64M | 190.06M | 125.33M | 131.72M |
| Current assets | 207.17M | 228.88M | 208.07M | 143.54M | 149.57M |
| Current liabilities | 29.65M | 30.84M | 21.03M | 19.06M | 12.15M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -42.32M | -39.65M | -28.78M | -14.83M | -16.58M |
| Investing cash flow | -1.69M | -1.02M | -962K | -2.54M | -6K |
| Financing cash flow | 20.21M | 59.14M | 94.86M | 10.99M | 49.53M |
| Change in cash | -23.8M | 18.46M | 65.11M | -6.38M | 32.94M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | SCHEDULE 13G/A — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| form 4 | Form 4 — Taylor Carolyn E. | View Filing | |
| form 4 | Form 4 — BAGGER RICHARD H | View Filing | |
| form 4 | Form 4 — GRANGE DAVID L | View Filing | |
| form 4 | Form 4 — Treco James | View Filing | |
| form 4 | Form 4 — Hunter James Randolph Jr | View Filing | |
| form 4 | Form 4 — Bell Margaret Smith | View Filing | |
| form 4 | Form 4 — OLUKOTUN ADEOYE Y | View Filing | |
| form 4 | Form 4 — Stillwell Richard Newcomb | View Filing | |
| edgar index | 10-Q — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| form 4 | Form 4 — LEDERMAN SETH | View Filing | |
| form 4 | Form 4 — LEDERMAN SETH | View Filing | |
| form 4 | Form 4 — LEDERMAN SETH | View Filing | |
| edgar index | DEF 14A — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | SCHEDULE 13G/A — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | PRE 14A — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| form 4 | Form 4 — LEDERMAN SETH | View Filing | |
| form 4 | Form 4 — LEDERMAN SETH | View Filing | |
| form 4 | Form 4 — LEDERMAN SETH | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | ARS — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 10-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 8-K — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| edgar index | 4 — Tonix Pharmaceuticals Holding Corp. | View Filing | |
| form 4 | Form 4 — LEDERMAN SETH | View Filing | |
| form 4 | Form 4 — LEDERMAN SETH | View Filing | |
| form 4 | Form 4 — Fogarty Siobhan | View Filing | |
| form 4 | Form 4 — Fogarty Siobhan | View Filing | |
| form 4 | Form 4 — SULLIVAN GREGORY M | View Filing | |
| form 4 | Form 4 — SULLIVAN GREGORY M | View Filing | |
| form 4 | Form 4 — SAENGER BRADLEY | View Filing | |
| form 4 | Form 4 — SAENGER BRADLEY | View Filing | |
| form 4 | Form 4 — MORRIS JESSICA EDGAR | View Filing |